Prime Medicine, Inc.
PM359
Chronic Granulomatous Disease (CGD)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on PM359 for Chronic Granulomatous Disease (CGD) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“The Company is working towards final alignment with the FDA, and intends to submit a Biologics License Application (BLA).”